Reuters reported on Friday, citing IQVIA data shared by analysts, that Novo’s weight-loss pill was prescribed 18,410 times in the week ended January 16.
The failed clinical program evaluated rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes.
Novo and Aspect have been collaborating since 2023 to develop cellular medicines, and said that the new partnership phase builds on the momentum achieved in the existing collaboration.
Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory diffuse large B-cell lymphoma, the company said.